Meeting
2016 Gastrointestinal Cancers Symposium
FOLFIRINOX for patients with borderline and never-resectable locally advanced pancreatic cancer, with the addition of chemoradiotherapy for potentially resectable patients: A phase II study.
Authors
Jon Kroll Bjerregaard
Department of Oncology, Odense University Hospital, Odense, Denmark
Jon Kroll Bjerregaard , Morten Ladekarl , Anna-Lene Fromm , Per Pfeiffer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT-01397019
Citation
J Clin Oncol 34, 2016 (suppl 4S; abstr 408)
DOI
10.1200/jco.2016.34.4_suppl.408
Abstract #
408
Poster Bd #
L2
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases (RCSM): Results of the FFCD 1102 phase II trial.
First Author: Jean Baptiste Bachet
Poster
2013 ASCO Annual Meeting
Phase II study of neoadjuvant chemotherapy with modified FOLFOXIRI in borderline resectable or unresectable stage III pancreatic cancer.
First Author: Enrico Vasile
Poster
2021 ASCO Annual Meeting
Randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer (JCOG1407).
First Author: Masato Ozaka
Poster
2020 ASCO Virtual Scientific Program
Pharmacokinetically-guided 5-FU dose optimization within the preoperative FOLFOXIRI regimen in resectable pancreatic cancer patients.
First Author: Anna Vilalta